Published in J Virol on February 01, 2004
Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A (2005) 1.45
Epstein-Barr virus nuclear protein EBNA3C is required for cell cycle progression and growth maintenance of lymphoblastoid cells. Proc Natl Acad Sci U S A (2006) 1.33
Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog (2010) 1.27
Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol (2004) 1.25
Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A (2011) 1.18
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol (2009) 1.18
Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology (2009) 1.18
SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol (2005) 1.17
A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol (2004) 1.10
Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One (2010) 1.10
Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol (2008) 1.08
Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog (2011) 1.07
Epstein-Barr virus nuclear protein EBNA3C residues critical for maintaining lymphoblastoid cell growth. Proc Natl Acad Sci U S A (2009) 1.07
Regulation of the retinoblastoma proteins by the human herpesviruses. Cell Div (2009) 1.02
The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol (2007) 1.02
EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes. Proc Natl Acad Sci U S A (2008) 1.01
Induction of p16(INK4a) is the major barrier to proliferation when Epstein-Barr virus (EBV) transforms primary B cells into lymphoblastoid cell lines. PLoS Pathog (2013) 1.01
The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog (2013) 1.00
Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog (2011) 0.96
EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol (2010) 0.93
The DNA damage response in viral-induced cellular transformation. Br J Cancer (2012) 0.92
E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog (2012) 0.89
Epstein-Barr virus EBNA-3C is targeted to and regulates expression from the bidirectional LMP-1/2B promoter. J Virol (2006) 0.89
Virus manipulation of cell cycle. Protoplasma (2011) 0.86
Upregulation of the cell-cycle regulator RGC-32 in Epstein-Barr virus-immortalized cells. PLoS One (2011) 0.85
Transcriptional downregulation of p27KIP1 through regulation of E2F function during LMP1-mediated transformation. J Virol (2009) 0.84
EBNA3C regulates p53 through induction of Aurora kinase B. Oncotarget (2015) 0.80
Role of EBNA-3 Family Proteins in EBV Associated B-cell Lymphomagenesis. Front Microbiol (2016) 0.76
An EBV recombinant deleted for residues 130-159 in EBNA3C can deregulate p53/Mdm2 and Cyclin D1/CDK6 which results in apoptosis and reduced cell proliferation. Oncotarget (2016) 0.75
Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening. Expert Opin Drug Discov (2010) 0.75
Deregulation of the cell cycle machinery by Epstein-Barr virus nuclear antigen 3C. Future Virol (2009) 0.75
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell (1993) 33.20
The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science (1989) 16.54
SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell (1988) 12.69
Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol (1997) 9.87
Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 9.79
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell (1994) 9.48
Cyclin A is required at two points in the human cell cycle. EMBO J (1992) 7.96
Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell (1992) 7.61
Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature (1989) 7.60
Cellular targets for transformation by the adenovirus E1A proteins. Cell (1989) 7.53
Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature (1996) 6.67
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med (1989) 6.66
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes Dev (1993) 6.02
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis. Genes Dev (1993) 5.33
Identification of G1 kinase activity for cdk6, a novel cyclin D partner. Mol Cell Biol (1994) 5.18
Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol (1993) 4.05
A cyclin A-protein kinase complex possesses sequence-specific DNA binding activity: p33cdk2 is a component of the E2F-cyclin A complex. Cell (1992) 3.64
Early events in Epstein-Barr virus infection of human B lymphocytes. Virology (1991) 3.60
Adenovirus 5 DNA sequences present and RNA sequences transcribed in transformed human embryo kidney cells (HEK-Ad-5 or 293). Virology (1979) 3.34
Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A. Proc Natl Acad Sci U S A (1998) 3.27
Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol (1990) 3.24
Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription. J Biol Chem (1997) 2.93
The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev (1997) 2.83
EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J (1994) 2.79
Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. Genes Dev (1994) 2.72
Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev (1997) 2.65
Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes Dev (1994) 2.32
Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol (1995) 2.25
Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1. Mol Cell Biol (1995) 2.11
EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proc Natl Acad Sci U S A (1993) 1.99
Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer (1967) 1.99
Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol (1999) 1.92
Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes Dev (1994) 1.91
Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene (1996) 1.83
Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B. J Virol (1993) 1.69
Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol (1994) 1.60
Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene (1996) 1.52
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol (2002) 1.45
Modulation of histone acetyltransferase activity through interaction of epstein-barr nuclear antigen 3C with prothymosin alpha. Mol Cell Biol (2000) 1.41
Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells. Nature (1996) 1.41
Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA. Int J Cancer (1975) 1.41
Epstein-Barr virus EBNA3C can disrupt multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene (2000) 1.36
Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene (1994) 1.32
The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. J Virol (1999) 1.20
The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. Mol Cell Biol (1997) 1.17
The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle. J Virol (1998) 1.11
The normal cell cycle activation program is exploited during the infection of quiescent B lymphocytes by Epstein-Barr virus. Cancer Res (1995) 1.06
The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription. J Virol (2002) 1.04
Epstein-Barr virus EBNA-LP and transcription regulation properties of pRB, p107 and p53 in transfection assays. J Gen Virol (1995) 0.97
Cell cycle: how, when and why cells get rid of cyclin A. Curr Biol (2001) 0.84
Human lymphotropic viruses associated with lymphoid malignancy: Epstein-Barr and HTLV-1. Hematol Oncol Clin North Am (1990) 0.79
EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog (2006) 1.71
Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther (2009) 1.52
Isolation and characterization of mouse and human esophageal epithelial cells in 3D organotypic culture. Nat Protoc (2012) 1.51
Induction of Kaposi's sarcoma-associated herpesvirus latency-associated nuclear antigen by the lytic transactivator RTA: a novel mechanism for establishment of latency. J Virol (2005) 1.47
Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A (2005) 1.45
Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol (2003) 1.43
Molecular biology and pathogenesis of Kaposi sarcoma-associated herpesvirus. FEMS Microbiol Lett (2003) 1.37
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen induces chromosomal instability through inhibition of p53 function. J Virol (2006) 1.36
Kaposi's sarcoma-associated herpesvirus latent protein LANA interacts with HIF-1 alpha to upregulate RTA expression during hypoxia: Latency control under low oxygen conditions. J Virol (2006) 1.30
miR-K12-7-5p encoded by Kaposi's sarcoma-associated herpesvirus stabilizes the latent state by targeting viral ORF50/RTA. PLoS One (2011) 1.29
Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One (2009) 1.26
Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes. Clin Cancer Res (2011) 1.25
Tumor viruses and cancer biology: Modulating signaling pathways for therapeutic intervention. Cancer Biol Ther (2010) 1.19
A potential alpha-helix motif in the amino terminus of LANA encoded by Kaposi's sarcoma-associated herpesvirus is critical for nuclear accumulation of HIF-1alpha in normoxia. J Virol (2007) 1.19
Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol (2009) 1.18
Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology (2009) 1.18
SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol (2005) 1.17
Protein complexes associated with the Kaposi's sarcoma-associated herpesvirus-encoded LANA. Virology (2007) 1.14
Hypoxia inactivates the VHL tumor suppressor through PIASy-mediated SUMO modification. PLoS One (2010) 1.12
A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol (2004) 1.10
Molecular biology of Kaposi's sarcoma-associated herpesvirus and related oncogenesis. Adv Virus Res (2010) 1.09
Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol (2008) 1.08
Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog (2011) 1.07
ORF73 of herpesvirus Saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats. J Virol (2003) 1.07
Kaposi's sarcoma-associated herpesvirus RTA activates the processivity factor ORF59 through interaction with RBP-Jkappa and a cis-acting RTA responsive element. Virology (2008) 1.05
The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription. J Virol (2002) 1.04
Proteomic analysis of the Kaposi's sarcoma-associated herpesvirus terminal repeat element binding proteins. J Virol (2006) 1.04
Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization. PLoS One (2010) 1.04
The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block. J Virol (2007) 1.02
Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. J Virol (2007) 1.02
The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog (2013) 1.00
H2AX phosphorylation is important for LANA-mediated Kaposi's sarcoma-associated herpesvirus episome persistence. J Virol (2013) 1.00
Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats. J Virol (2006) 0.99
Intracellular activated Notch1 is critical for proliferation of Kaposi's sarcoma-associated herpesvirus-associated B-lymphoma cell lines in vitro. J Virol (2006) 0.98
Kaposi's sarcoma-associated herpesvirus-encoded LANA can interact with the nuclear mitotic apparatus protein to regulate genome maintenance and segregation. J Virol (2008) 0.98
Epstein-Barr Virus nuclear antigen 1 (EBNA1) confers resistance to apoptosis in EBV-positive B-lymphoma cells through up-regulation of survivin. Virology (2010) 0.98
The minimal replicator element of the Kaposi's sarcoma-associated herpesvirus terminal repeat supports replication in a semiconservative and cell-cycle-dependent manner. J Virol (2006) 0.96
Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog (2011) 0.96
The single RBP-Jkappa site within the LANA promoter is crucial for establishing Kaposi's sarcoma-associated herpesvirus latency during primary infection. J Virol (2011) 0.95
Molecular biology of Kaposi's sarcoma-associated herpesvirus. Front Biosci (2002) 0.95
Bub1 and CENP-F can contribute to Kaposi's sarcoma-associated herpesvirus genome persistence by targeting LANA to kinetochores. J Virol (2010) 0.94
Kaposi's sarcoma herpesvirus-encoded latency-associated nuclear antigen stabilizes intracellular activated Notch by targeting the Sel10 protein. Proc Natl Acad Sci U S A (2007) 0.93
KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity. Virology (2006) 0.93
EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol (2010) 0.93
The RBP-Jκ binding sites within the RTA promoter regulate KSHV latent infection and cell proliferation. PLoS Pathog (2012) 0.93
The Epstein Barr nuclear antigen EBNA3C regulates transcription, cell transformation and cell migration. Front Biosci (2002) 0.92
A unique SUMO-2-interacting motif within LANA is essential for KSHV latency. PLoS Pathog (2013) 0.91
Kaposi's sarcoma herpesvirus upregulates Aurora A expression to promote p53 phosphorylation and ubiquitylation. PLoS Pathog (2012) 0.91
Nm23-H1 modulates the activity of the guanine exchange factor Dbl-1. Int J Cancer (2008) 0.91
ORF73 of herpesvirus saimiri, a viral homolog of Kaposi's sarcoma-associated herpesvirus, modulates the two cellular tumor suppressor proteins p53 and pRb. J Virol (2004) 0.91
Epstein-Barr virus nuclear antigen 1 interacts with Nm23-H1 in lymphoblastoid cell lines and inhibits its ability to suppress cell migration. J Virol (2005) 0.90
Kaposi's sarcoma-associated herpesvirus inhibits interleukin-4-mediated STAT6 phosphorylation to regulate apoptosis and maintain latency. J Virol (2010) 0.90
The suppressor of metastasis Nm23-H1 interacts with the Cdc42 Rho family member and the pleckstrin homology domain of oncoprotein Dbl-1 to suppress cell migration. Cancer Biol Ther (2008) 0.89
Epstein-Barr virus protein can upregulate cyclo-oxygenase-2 expression through association with the suppressor of metastasis Nm23-H1. J Virol (2006) 0.89
An autonomous replicating element within the KSHV genome. Cell Host Microbe (2007) 0.89
E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog (2012) 0.89
Single molecule analysis of replicated DNA reveals the usage of multiple KSHV genome regions for latent replication. PLoS Pathog (2011) 0.87
Intracellular-activated Notch1 can reactivate Kaposi's sarcoma-associated herpesvirus from latency. Virology (2006) 0.87
Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol (2014) 0.87
Molecular biology of EBV in relationship to AIDS-associated oncogenesis. Cancer Treat Res (2007) 0.86
Upregulation of cellular Bcl-2 by the KSHV encoded RTA promotes virion production. PLoS One (2011) 0.86
Cellular corepressor TLE2 inhibits replication-and-transcription- activator-mediated transactivation and lytic reactivation of Kaposi's sarcoma-associated herpesvirus. J Virol (2009) 0.86
Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis. Future Microbiol (2013) 0.86
Nucleoside diphosphate kinase/Nm23 and Epstein-Barr virus. Mol Cell Biochem (2009) 0.86
EBNA3C can modulate the activities of the transcription factor Necdin in association with metastasis suppressor protein Nm23-H1. J Virol (2008) 0.85
Nm23-H1 can induce cell cycle arrest and apoptosis in B cells. Cancer Biol Ther (2010) 0.85
Regulation of matrix metalloproteinase 9 expression by Epstein-Barr virus nuclear antigen 3C and the suppressor of metastasis Nm23-H1. J Virol (2005) 0.85
Multiple oncogenic viruses identified in Ocular surface squamous neoplasia in HIV-1 patients. Infect Agent Cancer (2010) 0.85
Expression of alpha V integrin is modulated by Epstein-Barr virus nuclear antigen 3C and the metastasis suppressor Nm23-H1 through interaction with the GATA-1 and Sp1 transcription factors. Virology (2006) 0.84
Carboxyl-terminal amino acids 1052 to 1082 of the latency-associated nuclear antigen (LANA) interact with RBP-Jκ and are responsible for LANA-mediated RTA repression. J Virol (2012) 0.83
Isolation of human peripheral blood mononuclear cells (PBMCs). Curr Protoc Microbiol (2007) 0.82
Clinical implications of human papillomavirus infection. Front Biosci (2002) 0.82
Kaposi's sarcoma-associated herpesvirus-encoded LANA contributes to viral latent replication by activating phosphorylation of survivin. J Virol (2014) 0.82
Functional modulation of the metastatic suppressor Nm23-H1 by oncogenic viruses. FEBS Lett (2011) 0.81
IRF-4-mediated CIITA transcription is blocked by KSHV encoded LANA to inhibit MHC II presentation. PLoS Pathog (2013) 0.81
Comprehensive analysis of LANA interacting proteins essential for viral genome tethering and persistence. PLoS One (2013) 0.80
Epstein-Barr virus latent antigens EBNA3C and EBNA1 modulate epithelial to mesenchymal transition of cancer cells associated with tumor metastasis. Tumour Biol (2014) 0.78
Epstein-Barr Virus (EBV): infection, propagation, quantitation, and storage. Curr Protoc Microbiol (2007) 0.78
A peptide-based inhibitor for prevention of B cell hyperproliferation induced by Epstein-Barr virus. Virology (2006) 0.77
Conserved cell cycle regulatory properties within the amino terminal domain of the Epstein-Barr virus nuclear antigen 3C. Virology (2005) 0.77
Molecular genetics of herpesviruses: a recombinant technology approach. Methods Mol Biol (2005) 0.76
Detection of Epstein-Barr virus in T-cell prolymphocytic leukemia cells in vitro. J Clin Virol (2008) 0.76
MTA1 expression is linked to ovarian cancer. Cancer Biol Ther (2008) 0.75
Regulation of the metastasis suppressor Nm23-H1 by tumor viruses. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75